Repligen/$RGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Ticker
$RGEN
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
1,778
Website
Repligen Metrics
BasicAdvanced
$6.6B
-
-$0.25
1.11
-
Price and volume
Market cap
$6.6B
Beta
1.11
52-week high
$182.52
52-week low
$102.97
Average daily volume
910K
Financial strength
Total debt to equity
34.435
Interest coverage (TTM)
2.03%
Profitability
EBITDA (TTM)
119.524
Gross margin (TTM)
51.29%
Net profit margin (TTM)
-2.05%
Operating margin (TTM)
6.87%
Effective tax rate (TTM)
-1.68%
Revenue per employee (TTM)
$380,000
Management effectiveness
Valuation
Price to revenue (TTM)
9.746
Price to book
3.31
Price to tangible book (TTM)
13.32
Growth
Revenue change (TTM)
8.73%
Earnings per share change (TTM)
-249.84%
3-year revenue growth (CAGR)
-4.70%
10-year revenue growth (CAGR)
24.73%
3-year earnings per share growth (CAGR)
-55.28%
10-year earnings per share growth (CAGR)
1.08%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Bulls say / Bears say
Repligen's Q1 2025 revenue increased by 10% to $169 million, with adjusted EPS rising 29% to $0.39, surpassing forecasts. (Investing.com)
The company completed the acquisition of Tantti Laboratory Inc., enhancing its offerings in protein and chromatography, and launched AVIPure dsRNA resin for mRNA therapeutics. (StockTitan)
Analysts have set 12-month price targets for Repligen, revealing an average target of $179.88, indicating potential upside from current levels. (Nasdaq)
Repligen's Q4 2024 adjusted EPS decreased to $0.44 from $0.48 in the previous year, and revenue growth was only 1%, indicating potential stagnation. (Investing.com)
The company's stock has seen a -24.53% return over the past year, reflecting investor concerns about its performance. (Investing.com)
Some analysts have downgraded their price targets, with Canaccord Genuity lowering its target from $170 to $150, suggesting reduced confidence in future growth. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repligen stock?
Repligen (RGEN) has a market cap of $6.6B as of August 01, 2025.
What is the P/E ratio for Repligen stock?
The price to earnings (P/E) ratio for Repligen (RGEN) stock is 0 as of August 01, 2025.
Does Repligen stock pay dividends?
No, Repligen (RGEN) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Repligen dividend payment date?
Repligen (RGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Repligen?
Repligen (RGEN) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.